|
1
|
Lee UE and Friedman SL: Mechanisms of
hepatic fibrogenesis. Best Pract Res Clin Gastroenterol.
25:195–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou WC, Zhang QB and Qiao L: Pathogenesis
of liver cirrhosis. World J Gastroenterol. 20:7312–7324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang CY, Yuan WG, He P, Lei JH and Wang
CX: Liver fibrosis and hepatic stellate cells: Etiology,
pathological hallmarks and therapeutic targets. World J
Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higashi T, Friedman SL and Hoshida Y:
Hepatic stellate cells as key target in liver fibrosis. Adv Drug
Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tacke F and Weiskirchen R: Update on
hepatic stellate cells: Pathogenic role in liver fibrosis and novel
isolation techniques. Expert Rev Gastroenterol Hepatol. 6:67–80.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang FS, Fan JG, Zhang Z, Gao B and Wang
HY: The global burden of liver disease: The major impact of China.
Hepatology. 60:2099–2108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manka P, Zeller A and Syn WK: Fibrosis in
chronic liver disease: An update on diagnostic and treatment
modalities. Drugs. 79:903–927. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sui M, Jiang X, Chen J, Yang H and Zhu Y:
Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic
stellate cell activation by regulating ferroptosis signaling
pathway. Biomed Pharmacother. 106:125–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng H, Wan LY, Liang JJ, Zhang YQ, Ai WB
and Wu JF: The roles of lncRNA in hepatic fibrosis. Cell Biosci.
8:632018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong Z, Li S, Wang X, Si L, Ma R, Bao L
and Bo A: lncRNA GAS5 restrains CCl4-induced hepatic
fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling
pathway. Am J Physiol Gastrointest Liver Physiol. 316:G539–G550.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen X, Guo H, Xu J and Wang J: Inhibition
of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis
by inhibiting the MAPK signaling pathway in rats with nonalcoholic
fatty liver disease. J Cell Physiol. 234:18169–18179. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu J, Bai J, Zhang X, Lv Y, Gong Y, Liu L,
Zhao H, Yu F, Ping Y, Zhang G, et al: A comprehensive overview of
lncRNA annotation resources. Brief Bioinform. 18:236–249.
2017.PubMed/NCBI
|
|
13
|
Yu F, Geng W, Dong P, Huang Z and Zheng J:
LncRNA-MEG3 inhibits activation of hepatic stellate cells through
SMO protein and miR-212. Cell Death Dis. 9:10142018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li YC, Wang D and Zhu GY: Increased
expression of long noncoding RNA AK021443 predicts worse clinical
outcome in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci.
22:4855–4860. 2018.PubMed/NCBI
|
|
15
|
Yang J, Li J, Liu B, Zhang R, Gu F, Zhao J
and Cheng S: Long noncoding RNA AK021443 promotes cell
proliferation and migration by regulating epithelial-mesenchymal
transition in hepatocellular carcinoma cells. DNA Cell Biol.
37:481–490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar MM and Goyal R: LncRNA as a
therapeutic target for angiogenesis. Curr Top Med Chem.
17:1750–1757. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Z, Jiang S, Shang J, Jiang Y, Dai Y,
Xu B, Yu Y, Liang Z and Yang Y: LncRNA: Shedding light on
mechanisms and opportunities in fibrosis and aging. Ageing Res Rev.
52:17–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang H, Shen H, Li J and Guo LW:
SIGMAR1/Sigma-1 receptor ablation impairs autophagosome clearance.
Autophagy. 15:1539–1557. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun L, Fan Z, Chen J, Tian W, Li M, Xu H,
Wu X, Shao J, Bian Y, Fang M and Xu Y: Transcriptional repression
of SIRT1 by protein inhibitor of activated STAT 4 (PIAS4) in
hepatic stellate cells contributes to liver fibrosis. Sci Rep.
6:284322016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee FT, Mountain AJ, Kelly MP, Hall C,
Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW
and Scott AM: Enhanced efficacy of radioimmunotherapy with
90Y-CHX-A′-DTPA-hu3S193 by inhibition of epidermal growth factor
receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor
AG1478. Clin Cancer Res. 11:7080s–7086s. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu N, Niu X, Wang Y, Du H, Wang B, Du J,
Li Y, Wang R, Zhang Y, Zhao S, et al: Role of LncRNA-activated by
transforming growth factor beta in the progression of hepatitis C
virus-related liver fibrosis. Discov Med. 22:29–42. 2016.PubMed/NCBI
|
|
23
|
Trautwein C, Friedman SL, Schuppan D and
Pinzani M: Hepatic fibrosis: Concept to treatment. J Hepatol. 62 (1
Suppl):S15–S24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duval F, Moreno-Cuevas JE, Gonzalez-Garza
MT, Rodriguez-Montalvo C and Cruz-Vega DE: Protective mechanisms of
medicinal plants targeting hepatic stellate cell activation and
extracellular matrix deposition in liver fibrosis. Chin Med.
9:272014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baglieri J, Brenner DA and Kisseleva T:
The role of fibrosis and liver-associated fibroblasts in the
pathogenesis of hepatocellular carcinoma. Int J Mol Sci.
20:17232019. View Article : Google Scholar
|
|
26
|
Liu WH, Song FQ, Ren LN, Guo WQ, Wang T,
Feng YX, Tang LJ and Li K: The multiple functional roles of
mesenchymal stem cells in participating in treating liver diseases.
J Cell Mol Med. 19:511–520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Georgakilas AG, Martin OA and Bonner WM:
p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang CH, Zhu XD, Ma DN, Sun HC, Gao DM,
Zhang N, Qin CD, Zhang YY, Ye BG, Cai H, et al: Flot2 promotes
tumor growth and metastasis through modulating cell cycle and
inducing epithelial-mesenchymal transition of hepatocellular
carcinoma. Am J Cancer Res. 7:1068–1083. 2017.PubMed/NCBI
|
|
29
|
Yamada S, Fuchs BC, Fujii T, Shimoyama Y,
Sugimoto H, Nomoto S, Takeda S, Tanabe KK, Kodera Y and Nakao A:
Epithelial-to-mesenchymal transition predicts prognosis of
pancreatic cancer. Surgery. 154:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wynn TA: Common and unique mechanisms
regulate fibrosis in various fibroproliferative diseases. J Clin
Invest. 117:524–529. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rockey DC, Bell PD and Hill JA: Fibrosis-a
common pathway to organ injury and failure. N Engl J Med.
373:962015.PubMed/NCBI
|
|
32
|
Birben E, Sahiner UM, Sackesen C, Erzurum
S and Kalayci O: Oxidative stress and antioxidant defense. World
Allergy Organ J. 5:9–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiu YN, Wang GH, Zhou F, Hao JJ, Tian L,
Guan LF, Geng XK, Ding YC, Wu HW and Zhang KZ: PM2.5 induces liver
fibrosis via triggering ROS-mediated mitophagy. Ecotoxicol Environ
Saf. 167:178–187. 2019. View Article : Google Scholar : PubMed/NCBI
|
